Mechanisms Underlying Synergistic Activity of KT-413, a Targeted Degrader of IRAK4 and IMiD Substrates in Hematopoietic Cancers Christine Klaus, Scott Rusin, Samya Bhaduri, Dirk Walther, Kirti Sharma, Michele Mayo, Alice McDonald, Matthew Weiss, Duncan Walker, Rahul Karnik Poster # LB118 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N April 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historic ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N March 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR (State or other jurisdiction of incorporation or organization) 200 Arsenal Yards Blvd., Suite 230 Watertown, Massachusetts 02472 (Address of principal executive offices) (Zip Code) Delaware 81-2992166 (I.R.S. Employer Identification No.) Registrant's telephone number, including area c ...

业绩总结 - 截至2020年第四季度，Kymera的现金余额约为4.58亿美元，预计可支持运营计划至2025年[7] - 第三季度合作收入为1450万美元，研发费用为1580万美元，管理费用为680万美元，净亏损为800万美元[88] - 公司已筹集超过6亿美元的资金，其中220百万美元来自合作伙伴的预付款[88] 研发管线与临床试验 - 公司预计到2021年底将有3个IND（临床试验申请）和临床启动[7] - Kymera的研发管线包括针对多种疾病的6个靶点，涵盖免疫炎症和肿瘤学领域[9] - KT-474在2021年第一季度将开始对脓疱性汗腺炎、特应性皮炎和类风湿关节炎等适应症进行临床试验[9] - KT-413的临床开发计划包括在2021年下半年提交IND申请，并在2022年建立临床生物学证明[64] 新产品与技术研发 - KT-474是一种首创的强效、选择性和口服活性的IRAK4降解剂，具有在多种免疫炎症疾病中的特许潜力[47] - KT-474在小鼠银屑病模型中，口服给药后可抑制皮肤增厚，效果与局部皮质类固醇相当，抑制率达到60-70%[37] - KT-413在多种MYD88突变的患者衍生异种移植模型中显示出>85%的肿瘤生长抑制[62] - 公司计划在2021年第一季度启动健康志愿者的Phase 1试验[91] 市场扩张与用户数据 - 目前在美国约有325,000人受到HS影响，其中约25%为中度至重度患者[45] - 参与研究的患者总数为40人，其中30人患有Hidradenitis Suppurativa (HS)，10人患有Atopic Dermatitis (AD)[95] - HS患者中，9人属于轻度，10人中度，11人重度，AD患者中有2人[95] 负面信息与挑战 - 目前正在进行的非干预性研究显示，IRAK4在病变和病变周围皮肤中的表达水平高于非病变皮肤[41] - 研究排除标准包括在过去3个月内使用生物治疗的患者[95] 其他新策略与有价值的信息 - 公司计划通过Pegasus平台开发组织选择性或限制性降解剂，以实现新的治疗机会[15] - 公司在未来的研发中将利用定量系统药理学模型来优化人类剂量[25] - STAT3降解剂在每两天给药时显著减少结直肠癌肿瘤生长，显示出对肿瘤微环境中免疫细胞的协同调节[80]

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

INVENTING NEW MEDICINES W I T H TA R G E T E D P R O T E I N D E G R A D AT I O N September 2020 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts ...